EpiPen Buyers Can't Appeal Order Yet In Antitrust Case

By Matthew Perlman · October 26, 2021, 4:30 PM EDT

EpiPen buyers can't immediately appeal an order that dismissed racketeering claims from its case accusing Mylan of scheming to inflate the price of the emergency allergy treatment, a Kansas federal judge...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Recent Articles By Matthew

July 17, 2024
Boehringer Wants Inhaler Antitrust Case Moved To Mass.
July 10, 2024
Buyers Say Teva Had Multipart Scheme To Delay Inhaler Rivals
July 09, 2024
FTC Says Drug Middlemen Inflate Costs, Squeeze Pharmacies
June 24, 2024
Justices Won't Hear Objections To $2.67B BCBS Deal
June 10, 2024
Health Data Co. Says Rival's Request Risks Patient Security
June 04, 2024
Nurse Staffing Exec Wants Antitrust, Fraud Charges Separated
May 28, 2024
HIV Drug Buyers Fight Bid To Combine 9th Circ. Appeal Briefs
May 24, 2024
Software-Aided Price Fixing Under Antitrust Assault
May 16, 2024
Gilead, Teva Want 17 HIV Drug Antitrust Appeals Consolidated
May 13, 2024
2nd Circ. Affirms Dismissal Of Bystolic Antitrust Suit